Target- |
MechanismImmunostimulants |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
MechanismCell replacements |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Phase I/II Trial of Tumor Vaccine in Post Radical Operation Patients With Lung Cancer
Tumor vaccines may make the body build an immune response to kill tumor cells. This research study is evaluating a new type of tumor vaccine termed as "Neoantigen Tumor Vaccine". The purpose of this phase I/II trial study is to assess the safety and effectiveness of neoantigentumor vaccine in post radical operation patients with stage IIIA lung cancer.
Phase I Study of High Efficient Killing Cell Therapy for Advanced Non Small Cell Lung Cancer
The purpose of this study to preliminarily evaluate the safety and efficacy of High Efficient Killing Cell Therapy for refractory and advanced non-small cell lung cancer
A Phase 1/2 Safety and Efficacy Study of Natural Killer and Natural Killer T Cell Immunotherapy in Patients With Non Small Cell Lung Cancer
The purpose of this study is to assess the safety and effectiveness of natural killer (NK) cell and natural killer T (NKT) cell-based immunotherapy in subjects with non small cell lung cancer.
100 Clinical Results associated with Shanghai Houchao Biotechnology Co., Ltd.
0 Patents (Medical) associated with Shanghai Houchao Biotechnology Co., Ltd.
100 Deals associated with Shanghai Houchao Biotechnology Co., Ltd.
100 Translational Medicine associated with Shanghai Houchao Biotechnology Co., Ltd.